215 related articles for article (PubMed ID: 18518768)
1. Combating immunosuppression in glioma.
Vega EA; Graner MW; Sampson JH
Future Oncol; 2008 Jun; 4(3):433-42. PubMed ID: 18518768
[TBL] [Abstract][Full Text] [Related]
2. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
Fecci PE; Ochiai H; Mitchell DA; Grossi PM; Sweeney AE; Archer GE; Cummings T; Allison JP; Bigner DD; Sampson JH
Clin Cancer Res; 2007 Apr; 13(7):2158-67. PubMed ID: 17404100
[TBL] [Abstract][Full Text] [Related]
3. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
[TBL] [Abstract][Full Text] [Related]
4. The role of regulatory T-cells in glioma immunology.
Ooi YC; Tran P; Ung N; Thill K; Trang A; Fong BM; Nagasawa DT; Lim M; Yang I
Clin Neurol Neurosurg; 2014 Apr; 119():125-32. PubMed ID: 24582432
[TBL] [Abstract][Full Text] [Related]
5. The role of regulatory T cells in malignant glioma.
Sonabend AM; Rolle CE; Lesniak MS
Anticancer Res; 2008; 28(2B):1143-50. PubMed ID: 18505050
[TBL] [Abstract][Full Text] [Related]
6. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
Jachimczak P; Bogdahn U; Schneider J; Behl C; Meixensberger J; Apfel R; Dörries R; Schlingensiepen KH; Brysch W
J Neurosurg; 1993 Jun; 78(6):944-51. PubMed ID: 8487077
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of immune evasion by gliomas.
Rolle CE; Sengupta S; Lesniak MS
Adv Exp Med Biol; 2012; 746():53-76. PubMed ID: 22639159
[TBL] [Abstract][Full Text] [Related]
8. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of central and peripheral immunomodulation in a murine glioma model.
Kennedy BC; Maier LM; D'Amico R; Mandigo CE; Fontana EJ; Waziri A; Assanah MC; Canoll P; Anderson RC; Anderson DE; Bruce JN
BMC Immunol; 2009 Feb; 10():11. PubMed ID: 19226468
[TBL] [Abstract][Full Text] [Related]
10. Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma.
Ochs K; Sahm F; Opitz CA; Lanz TV; Oezen I; Couraud PO; von Deimling A; Wick W; Platten M
J Neuroimmunol; 2013 Dec; 265(1-2):106-16. PubMed ID: 24090655
[TBL] [Abstract][Full Text] [Related]
11. Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells.
Domenis R; Cesselli D; Toffoletto B; Bourkoula E; Caponnetto F; Manini I; Beltrami AP; Ius T; Skrap M; Di Loreto C; Gri G
PLoS One; 2017; 12(1):e0169932. PubMed ID: 28107450
[TBL] [Abstract][Full Text] [Related]
12. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.
El Andaloussi A; Han Y; Lesniak MS
J Neurosurg; 2006 Sep; 105(3):430-7. PubMed ID: 16961139
[TBL] [Abstract][Full Text] [Related]
13. [The immunosuppressive microenvironment of malignant gliomas].
Borisov KE; Sakaeva DD
Arkh Patol; 2015; 77(6):54-63. PubMed ID: 26841651
[TBL] [Abstract][Full Text] [Related]
14. The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
Humphries W; Wei J; Sampson JH; Heimberger AB
Neurosurg Clin N Am; 2010 Jan; 21(1):125-37. PubMed ID: 19944972
[TBL] [Abstract][Full Text] [Related]
15. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Jordan JT; Sun W; Hussain SF; DeAngulo G; Prabhu SS; Heimberger AB
Cancer Immunol Immunother; 2008 Jan; 57(1):123-31. PubMed ID: 17522861
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene.
Liau LM; Fakhrai H; Black KL
Neurol Res; 1998 Dec; 20(8):742-7. PubMed ID: 9864741
[TBL] [Abstract][Full Text] [Related]
17. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Fecci PE; Mitchell DA; Whitesides JF; Xie W; Friedman AH; Archer GE; Herndon JE; Bigner DD; Dranoff G; Sampson JH
Cancer Res; 2006 Mar; 66(6):3294-302. PubMed ID: 16540683
[TBL] [Abstract][Full Text] [Related]
18. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells.
Hilchey SP; De A; Rimsza LM; Bankert RB; Bernstein SH
J Immunol; 2007 Apr; 178(7):4051-61. PubMed ID: 17371959
[TBL] [Abstract][Full Text] [Related]
19. Basic concepts in glioma immunology.
Parney IF
Adv Exp Med Biol; 2012; 746():42-52. PubMed ID: 22639158
[TBL] [Abstract][Full Text] [Related]
20. Hydrogen-Rich Saline Ameliorates Allergic Rhinitis by Reversing the Imbalance of Th1/Th2 and Up-Regulation of CD4+CD25+Foxp3+Regulatory T Cells, Interleukin-10, and Membrane-Bound Transforming Growth Factor-β in Guinea Pigs.
Xu F; Yu S; Qin M; Mao Y; Jin L; Che N; Liu S; Ge R
Inflammation; 2018 Feb; 41(1):81-92. PubMed ID: 28894978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
